Meeting
2016 ASCO Annual Meeting
Impact of landmark responses on 3-year (yr) outcomes with ponatinib in heavily pretreated CP-CML patients (pts).
Authors
Martin C. Müller
Universitatsmedizin Mannheim, Mannheim, Mannheim, Germany
Martin C. Müller , Michele Baccarani , Michael W.N. Deininger , Francois Guilhot , Andreas Hochhaus , Timothy P. Hughes , Neil P. Shah , Moshe Talpaz , Stephanie Lustgarten , Victor M Rivera , Timothy Piers Clackson , Frank G. Haluska , Jorge E. Cortes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Chronic Leukemia—CML
Clinical Trial Registration Number
NCT01207440
Citation
J Clin Oncol 34, 2016 (suppl; abstr 7053)
DOI
10.1200/JCO.2016.34.15_suppl.7053
Abstract #
7053
Poster Bd #
45
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Phase 3 PhALLCON study: Ponatinib (PON) versus imatinib (IM) with reduced-intensity chemotherapy (CT) in patients (pts) with newly diagnosed Philadelphia chromosome–positive (Ph+) ALL.
First Author: Elias Jabbour
Poster
2017 ASCO Annual Meeting
Impact of early landmark responses with ponatinib on 4-yr outcomes in CP-CML patients (pts) in PACE, a pivotal phase II trial.
First Author: Martin Mueller
Poster
2016 ASCO Annual Meeting
4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia.
First Author: Jorge E. Cortes
Poster
2014 ASCO Annual Meeting
Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: Longer-term follow up of the PACE trial.
First Author: Hagop M. Kantarjian